Cochrane · systematic review · CD011313
Yttrium-90 microsphere radioembolisation for unresectable hepatocellular carcinoma
Abdel-Rahman Omar, Elsayed Zeinab · Cochrane Database of Systematic Reviews · 2020 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
21
current version
GRADE rated
13
No studies
8
Included studies
NR
No studies 8 · 38.1%Ungraded 0 · 0%Very low 12 · 57.1%Low 1 · 4.8%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyRadioembolisation plus sorafenib compared with sorafenib monotherapy for unresectable hepatocellular carcinoma
Population: people with hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at 1 year Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | NR | No studies |
Health‐related quality of life Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | NR | No studies |
Serious adverse events Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | 1 study · 341 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Cancer‐related mortality Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | NR | No studies |
Time to progression of the tumour (median time to progression) Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | NR | No studies |
Tumour response assessments Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | NR | No studies |
Non‐serious adverse events (hyperbilirubinaemia: most frequent) Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | 1 study · 341 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Radioembolisation compared with sorafenib for unresectable hepatocellular carcinoma
Population: people with hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at 1 year Radioembolisation vs sorafenib | no estimate extracted | 1 study · 360 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Health‐related quality of life Radioembolisation vs sorafenib | no estimate extracted | 1 study · 360 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Serious adverse events Radioembolisation vs sorafenib | no estimate extracted | 1 study · 360 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Cancer‐related mortality Radioembolisation vs sorafenib | no estimate extracted | NR | No studies |
Time to progression of the tumour (median time to progression) Radioembolisation vs sorafenib | no estimate extracted | 1 study · 360 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Disease control rate Radioembolisation vs sorafenib | RR 0.94 [0.84, 1.05] | 2 studies · 748 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Non‐serious adverse events (hand‐foot skin reaction) Radioembolisation vs sorafenib | RR 0.02 [0, 0.06] | 2 studies · 734 participants | Low Downgraded: risk of bias, publication bias |
Radioembolisation compared with chemoembolisation for unresectable hepatocellular carcinoma
Population: people with hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
All‐cause mortality at 1 year Radioembolisation vs chemoembolisation | no estimate extracted | NR | No studies |
Health‐related quality of life Radioembolisation vs chemoembolisation | no estimate extracted | 1 study · 28 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Serious adverse events Radioembolisation vs chemoembolisation | RR 1.44 | 3 studies · 97 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Cancer‐related mortality Radioembolisation vs chemoembolisation | no estimate extracted | NR | No studies |
Time to progression of the tumour (median time to progression) Radioembolisation vs chemoembolisation | no estimate extracted | 3 studies · 97 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Disease control rate Radioembolisation vs chemoembolisation | no estimate extracted | 3 studies · 97 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Non‐serious adverse events Radioembolisation vs chemoembolisation | no estimate extracted | 3 studies · 97 participants | Very low Downgraded: risk of bias, imprecision, publication bias |
Radioembolisation compared with chemoembolisation for intermediate‐stage hepatocellular carcinoma
Population: people with hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
HRQoL Radioembolisation vs chemoembolisation | no estimate extracted | 1 study · 28 participants | Very low |
SAEs Radioembolisation vs chemoembolisation | no estimate extracted | 1 study · 28 participants | Very low |
Median PFS Radioembolisation vs chemoembolisation | no estimate extracted | 1 study · 28 participants | Very low |
DCR Radioembolisation vs chemoembolisation | no estimate extracted | 1 study · 28 participants | Very low |
Non‐serious adverse events Radioembolisation vs chemoembolisation | no estimate extracted | 1 study · 28 participants | Very low |
Radioembolisation plus sorafenib compared with sorafenib monotherapy for unresectable hepatocellular carcinoma
Population: people with hepatocellular carcinoma
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Non‐serious adverse events Radioembolisation plus sorafenib vs sorafenib monotherapy | no estimate extracted | 1 study · 40 participants | Very low |